Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression < 50%.

Regulatory Milestone

Drug Profile & Mechanism of Action

• Glecirasib: KRAS G12C inhibitor targeting the specific oncogenic mutation driving tumor growth
• AST24082: Novel, highly selective SHP2 inhibitor in oral capsule form that enhances KRAS pathway inhibition
• Combination Rationale: Dual blockade of KRAS G12C and SHP2 produces synergistic anti-tumor effects by comprehensively inhibiting the MAPK signaling pathway
• Administration: Oral regimen offering potential convenience advantages over intravenous standard-of-care therapies

Clinical Data – Early Exploratory Studies

Market Context & Competitive Landscape

Strategic Implications & Commercial Outlook

• First-Mover Advantage: Potential to become first approved targeted therapy for KRAS G12C-mutant NSCLC in China’s first-line setting
• Market Premium: Targeted therapies typically command significant pricing premiums over chemotherapy-based regimens
• Development Acceleration: BTD status enables expedited regulatory review and potential priority approval pathways
• Global Expansion Potential: Strong clinical data could support international partnerships or regulatory filings in other markets
• Pipeline Validation: Success validates Allist’s precision oncology strategy and SHP2 inhibitor platform technology

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory outcomes, and commercial potential. Actual results may differ due to risks including pivotal trial outcomes, regulatory decisions, and competitive developments in the KRAS-targeted therapy space.-Fineline Info & Tech